{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:34:14Z","timestamp":1768451654606,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejca.2021.07.029","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T01:16:38Z","timestamp":1631150198000},"page":"153-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5693","authenticated-orcid":false,"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann","family":"Godbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Dalban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Illouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Wassermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-8674","authenticated-orcid":false,"given":"St\u00e9phane","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slimane","family":"Zerdoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-1201","authenticated-orcid":false,"given":"C\u00e9cile N.","family":"Chougnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Zalzali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Benisvy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Niccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Digue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3640-1204","authenticated-orcid":false,"given":"Livia","family":"Lamartina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2515-7840","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Borson Chazot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-8502","authenticated-orcid":false,"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12 Pt 1","key":"10.1016\/j.ejca.2021.07.029_bib1","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.lpm.2011.09.011","article-title":"Refractory thyroid cancers","volume":"40","author":"Schlumberger","year":"2011","journal-title":"Presse Med"},{"key":"10.1016\/j.ejca.2021.07.029_bib2","series-title":"WHO classification of tumours of endocrine organs","author":"Lloyd","year":"2017"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.029_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ando.2017.04.023","article-title":"Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery","volume":"78","author":"Zerdoud","year":"2017","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.029_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.ejca.2021.07.029_bib5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cncr.30360","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed?","volume":"123","author":"Haugen","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2021.07.029_bib6","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2021.07.029_bib7","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ejca.2021.07.029_bib8","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bulcan.2019.04.012","article-title":"The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF([R)) network review","volume":"106","author":"de la Fouchardiere","year":"2019","journal-title":"Bull Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.029_bib9","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1210\/jc.2010-0800","article-title":"Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer","volume":"95","author":"Fagin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ejca.2021.07.029_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.029_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1590\/2359-3997000000245","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation","volume":"61","author":"Schmidt","year":"2017","journal-title":"Arch Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ejca.2021.07.029_bib12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoto.2013.760","article-title":"Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer","volume":"138","author":"Nixon","year":"2012","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"9940","key":"10.1016\/j.ejca.2021.07.029_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejca.2021.07.029_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2021.07.029_bib15","doi-asserted-by":"crossref","first-page":"e3027","DOI":"10.1210\/clinem\/dgab196","article-title":"Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ejca.2021.07.029_bib16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.07.029_bib17","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1016\/S0959-8049(16)31549-0","article-title":"2805 Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): an updated analysis","volume":"51","author":"Guo","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.029_bib18","doi-asserted-by":"crossref","first-page":"vi329","DOI":"10.1093\/annonc\/mdw376.06","article-title":"Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: an exploratory crossover adjustment analyses","volume":"27","author":"Brose","year":"2016","journal-title":"Ann Oncol"},{"issue":"9964","key":"10.1016\/j.ejca.2021.07.029_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(15)60056-3","article-title":"Sorafenib for patients with differentiated thyroid cancer--authors' reply","volume":"385","author":"Brose","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2021.07.029_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2021.07.029_bib21","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(16)00038-3","article-title":"Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254","volume":"17","author":"Thanarajasingam","year":"2016","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.ejca.2021.07.029_bib22","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2017.77.1485","article-title":"Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma","volume":"36","author":"Jonasch","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.029_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2018.12.006","article-title":"The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: a phase 2 clinical trial","volume":"108","author":"Bjarnason","year":"2019","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2021.07.029_bib24","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","article-title":"RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial","volume":"26","author":"Lee","year":"2015","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2021.07.029_bib25","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1158\/1078-0432.CCR-18-3502","article-title":"Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer patients with central nervous system metastases","volume":"25","author":"Morikawa","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2021.07.029_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/jjco\/hyz088","article-title":"Phase I\/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L)","volume":"49","author":"Kimura","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.07.029_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2021.07.029_bib28","series-title":"ESMO 2020 virtual congress","article-title":"A multicenter, randomized, double-blind, phase 2 study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg","author":"Brose","year":"2020"},{"issue":"35","key":"10.1016\/j.ejca.2021.07.029_bib29","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2021.07.029_bib30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","article-title":"Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2021.07.029_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2021.07.029_bib32","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.029_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1186\/s12885-019-6369-7","article-title":"A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine","volume":"19","author":"Fleeman","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2021.07.029_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921004871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:34:08Z","timestamp":1760733248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921004871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":34,"alternative-id":["S0959804921004871"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}